Show the full website


Novo Holdings increases stakes on German Novo partner – adds EUR 50m investment

German Evotec has raised DKK 1.9bn (EUR 255m), out of which the EUR 50m stem from Novo Holdings, by which the latter increases its stakes in the biotech and contract research firm, which recently started its partnership with Novo Nordisk in chronic kidney diseases.

Foto: Novo Holdings / PR

Novo Holdings, the ultimate owner of Novo Nordisk, still sees great opportunities in the German biotech and contract research company Evotec, which the Danish billion kroner fund first bought into in February 2017.

By this, the fund increases its stakes in the company with a EUR 50m investment, which arrives at the same time as Evotec lets in a new main investor in the form of the investment firm Mubadala Investment Company.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Receive newsletter from MedWatch today

NB: Subscribing to the newsletter is free.

More from MedWatch


See all jobs